Advertisement

Incremental Value of Late Gadolinium Enhancement for Management of Patients With Hypertrophic Cardiomyopathy

      Cardiac magnetic resonance with late gadolinium enhancement (LGE) is a well-established method for in vivo detection of myocardial scarring. Several recent studies have investigated the prognostic value of LGE in patients with hypertrophic cardiomyopathy (HC). We discuss the prevalence and patterns of scarring in HC and its pathophysiologic significance, with focus on ventricular arrhythmias and sudden cardiac death. The available evidence that myocardial scar demonstrated by LGE is a good independent predictor of cardiac mortality in HC is summed up. Recommendations of current guidelines for prevention of sudden cardiac death in HC are discussed with regard to recent results, and the significance of LGE as an emerging risk factor is pointed out. In conclusion, it is demonstrated that LGE has incremental value in addition to clinical risk factors for risk stratification and management of patients with HC.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cannan C.R.
        • Reeder G.S.
        • Bailey K.R.
        • Melton III, L.J.
        • Gersh B.J.
        Natural history of hypertrophic cardiomyopathy.
        Circulation. 1995; 92: 2488-2495
        • Maron B.J.
        • Olivotto I.
        • Spirito P.
        • Casey S.A.
        • Bellone P.
        • Gohman T.E.
        • Graham K.J.
        • Burton D.A.
        • Cecchi F.
        Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population.
        Circulation. 2000; 102: 858-864
        • Maron B.J.
        Sudden death in young athletes.
        N Engl J Med. 2003; 349: 1064-1075
        • Maron B.J.
        • McKenna W.J.
        • Danielson G.K.
        • Kappenberger L.J.
        • Kuhn H.J.
        • Seidman C.E.
        • Shah P.M.
        • Spencer III, W.H.
        • Spirito P.
        • Ten Cate F.J.
        • Wigle E.D.
        American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy.
        Eur Heart J. 2003; 24: 1965-1991
        • Harris K.M.
        • Spirito P.
        • Maron M.S.
        • Zenovich A.G.
        • Formisano F.
        • Lesser J.R.
        • Mackey-Bojack S.
        • Manning W.J.
        • Udelson J.E.
        • Maron B.J.
        Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy.
        Circulation. 2006; 114: 216-225
        • Maron B.J.
        • Spirito P.
        Implications of left ventricular remodeling in hypertrophic cardiomyopathy.
        Am J Cardiol. 1998; 81: 1339-1344
        • Melacini P.
        • Basso C.
        • Angelini A.
        • Calore C.
        • Bobbo F.
        • Tokajuk B.
        • Bellini N.
        • Smaniotto G.
        • Zucchetto M.
        • Iliceto S.
        • Thiene G.
        • Maron B.J.
        Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy.
        Eur Heart J. 2010; 31: 2111-2123
        • Wagner A.
        • Mahrholdt H.
        • Holly T.A.
        • Elliott M.D.
        • Regenfus M.
        • Parker M.
        • Klocke F.J.
        • Bonow R.O.
        • Kim R.J.
        • Judd R.M.
        Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study.
        Lancet. 2003; 361: 374-379
        • Bello D.
        • Einhorn A.
        • Kaushal R.
        • Kenchaiah S.
        • Raney A.
        • Fieno D.
        • Narula J.
        • Goldberger J.
        • Shivkumar K.
        • Subacius H.
        • Kadish A.
        Cardiac magnetic resonance imaging: infarct size is an independent predictor of mortality in patients with coronary artery disease.
        Magn Reson Imaging. 2011; 29: 50-56
        • Wu K.C.
        • Weiss R.G.
        • Thiemann D.R.
        • Kitagawa K.
        • Schmidt A.
        • Dalal D.
        • Lai S.
        • Bluemke D.A.
        • Gerstenblith G.
        • Marbán E.
        • Tomaselli G.F.
        • Lima J.A.
        Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy.
        J Am Coll Cardiol. 2008; 51: 2414-2421
        • Elliott P.M.
        • Sharma S.
        • Varnava A.
        • Poloniecki J.
        • Rowland E.
        • McKenna W.J.
        Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 1999; 33: 1596-1601
        • Varnava A.M.
        • Elliott P.M.
        • Mahon N.
        • Davies M.J.
        • McKenna W.J.
        Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy.
        Am J Cardiol. 2001; 88: 275-279
        • Maron B.J.
        • Shen W.K.
        • Link M.S.
        • Epstein A.E.
        • Almquist A.K.
        • Daubert J.P.
        • Bardy G.H.
        • Favale S.
        • Rea R.F.
        • Boriani G.
        • Estes III, N.A.
        • Spirito P.
        Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
        N Engl J Med. 2000; 342: 365-373
        • Choudhury L.
        • Mahrholdt H.
        • Wagner A.
        • Choi K.M.
        • Elliott M.D.
        • Klocke F.J.
        • Bonow R.O.
        • Judd R.M.
        • Kim R.J.
        Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2002; 40: 2156-2164
        • Bruder O.
        • Wagner A.
        • Jensen C.J.
        • Schneider S.
        • Ong P.
        • Kispert E.M.
        • Nassenstein K.
        • Schlosser T.
        • Sabin G.V.
        • Sechtem U.
        • Mahrholdt H.
        Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2010; 56: 875-887
        • Moon J.C.
        • McKenna W.J.
        • McCrohon J.A.
        • Elliott P.M.
        • Smith G.C.
        • Pennell D.J.
        Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.
        J Am Coll Cardiol. 2003; 41: 1561-1567
        • Adabag A.S.
        • Maron B.J.
        • Appelbaum E.
        • Harrigan C.J.
        • Buros J.L.
        • Gibson C.M.
        • Lesser J.R.
        • Hanna C.A.
        • Udelson J.E.
        • Manning W.J.
        • Maron M.S.
        Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance.
        J Am Coll Cardiol. 2008; 51: 1369-1374
        • Maron B.J.
        • Spirito P.
        • Shen W.K.
        • Haas T.S.
        • Formisano F.
        • Link M.S.
        Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
        JAMA. 2007; 298 (erratum JAMA 2007;298:1516): 405-412
        • Jayatilleke I.
        • Doolan A.
        • Ingles J.
        • McGuire M.
        • Booth V.
        • Richmond D.R.
        • Semsarian C.
        Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy.
        Am J Cardiol. 2004; 93: 1192-1194
        • Gersh B.J.
        • Maron B.J.
        • Bonow R.O.
        • Dearani J.A.
        • Fifer M.A.
        • Link M.S.
        • Naidu S.S.
        • Nishimura R.A.
        • Ommen S.R.
        • Rakowski H.
        • Seidman C.E.
        • Towbin J.A.
        • Udelson J.E.
        • Yancy C.W.
        2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2011; 124: 2761-2796
        • Rickers C.
        • Wilke N.M.
        • Jerosch-Herold M.
        • Casey S.A.
        • Panse P.
        • Panse N.
        • Weil J.
        • Zenovich A.G.
        • Maron B.J.
        Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy.
        Circulation. 2005; 112: 855-861
        • Elliott P.M.
        • Poloniecki J.
        • Dickie S.
        • Sharma S.
        • Monserrat L.
        • Varnava A.
        • Mahon N.G.
        • McKenna W.J.
        Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.
        J Am Coll Cardiol. 2000; 36: 2212-2218
        • Elliott P.
        • Gimeno J.
        • Tomé M.
        • McKenna W.
        Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy.
        Eur Heart J. 2006; 27: 3073
        • Maron M.S.
        • Appelbaum E.
        • Harrigan C.J.
        • Buros J.
        • Gibson C.M.
        • Hanna C.
        • Lesser J.R.
        • Udelson J.E.
        • Manning W.J.
        • Maron B.J.
        Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.
        Circ Heart Fail. 2008; 1: 184-191
        • O'Hanlon R.
        • Grasso A.
        • Roughton M.
        • Moon J.C.
        • Clark S.
        • Wage R.
        • Webb J.
        • Kulkarni M.
        • Dawson D.
        • Sulaibeekh L.
        • Chandrasekaran B.
        • Bucciarelli-Ducci C.
        • Pasquale F.
        • Cowie M.R.
        • McKenna W.J.
        • Sheppard M.N.
        • Elliott P.M.
        • Pennell D.J.
        • Prasad S.K.
        Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2010; 56: 867-874
        • Rubinshtein R.
        • Glockner J.F.
        • Ommen S.R.
        • Araoz P.A.
        • Ackerman M.J.
        • Sorajja P.
        • Bos J.M.
        • Tajik A.J.
        • Valeti U.S.
        • Nishimura R.A.
        • Gersh B.J.
        Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
        Circ Heart Fail. 2010; 3: 51-58
        • Green J.J.
        • Berger J.S.
        • Kramer C.M.
        • Salerno M.
        Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
        JACC Cardiovasc Imaging. 2012; 5: 370-377
        • Maron B.J.
        Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy.
        Circ J. 2010; 74: 2271-2282